Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

52 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Keech A, et al. Among authors: Forder P. Lancet. 2005 Nov 26;366(9500):1849-61. doi: 10.1016/S0140-6736(05)67667-2. Lancet. 2005. PMID: 16310551 Clinical Trial.
Total mortality was 6.6% in the placebo group and 7.3% in the fenofibrate group (p=0.18). Fenofibrate was associated with less albuminuria progression (p=0.002), and less retinopathy needing laser treatment (5.2%vs 3.6%, p=0.0003). There was a slight increase in pancreatitis (0.5%vs 0.8%, p=0.031) and pulmonary embolism (0.7%vs 1.1%, p=0.022), but no other significant adverse effects. ...
Total mortality was 6.6% in the placebo group and 7.3% in the fenofibrate group (p=0.18). Fenofibrate was associated with less albumi …
Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Tonkin A, Hunt D, Voysey M, Kesäniemi A, Hamer A, Waites J, Mahar L, Mann S, Glasziou P, Forder P, Simes J, Keech AC; FIELD Study Investigators. Tonkin A, et al. Among authors: Forder P. Am Heart J. 2012 Mar;163(3):508-14. doi: 10.1016/j.ahj.2011.12.004. Am Heart J. 2012. PMID: 22424024 Clinical Trial.
The borderline difference in the effects of fenofibrate between those who did (hazard ratio [HR] 1.02, 95% CI 0.86-1.20) and did not have prior CVD (HR 0.81, 95% CI 0.70-0.94; heterogeneity P = .045) became nonsignificant after adjustment for baseline covariates and other CVD medications (HR 0.96, 95% CI 0.81-1.14 vs HR 0.78, 95% CI 0.67-0.90) (heterogeneity P = .06). ...
The borderline difference in the effects of fenofibrate between those who did (hazard ratio [HR] 1.02, 95% CI 0.86-1.20) and did not have pr …
Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W, Forder P, Simes J, Hunt D, Tonkin A; LIPID Investigators. Hague W, et al. Among authors: Forder P. Am Heart J. 2003 Apr;145(4):643-51. doi: 10.1067/mhj.2003.1. Am Heart J. 2003. PMID: 12679760 Clinical Trial.
RESULTS: Women were at a lesser risk than men for death from any cause (10.3% vs 14.8%, P <.01), death from coronary heart disease (6.6% vs 8.6%, P =.04), and coronary revascularization (13.6% vs 16.2%, P =.05) and at a similar risk of myocardial infarction (9.2% vs 10.5%, P =.26), stroke (3.6% vs 4.7%, P =.11), and hospitalization for unstable angina (25.1% vs 24.5%, P = 0.90). ...Relative treatment effects in women did not differ significantly from those in men (P >.05) for any events except hospitalization for unstable angina. ...
RESULTS: Women were at a lesser risk than men for death from any cause (10.3% vs 14.8%, P <.01), death from coronary heart disease …
Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.
Sullivan D, Forder P, Simes J, Whiting M, Kritharides L, Merrifield A, Donoghoe M, Colman PG, Graham N, Haapamäki H, Keech A; FIELD Study Investigators. Sullivan D, et al. Among authors: Forder P. Diabetes Res Clin Pract. 2011 Nov;94(2):284-90. doi: 10.1016/j.diabres.2011.07.028. Epub 2011 Aug 21. Diabetes Res Clin Pract. 2011. PMID: 21862166 Clinical Trial.
Metformin was associated with higher levels of lipids (other than LDL-C) and homocysteine (P<0.001). Sulphonylurea-treated patients had a longer history of diabetes and more CVD and microvascular disease. Sulphonylurea treatment was associated with higher plasma creatinine and lower plasma HDL-C (P<0.001). The risks of all CVD outcomes were higher for those on sulphonylureas than diet alone, but were nonsignificant after adjustment for the duration and intensity of diabetes and severity of risk factors. ...
Metformin was associated with higher levels of lipids (other than LDL-C) and homocysteine (P<0.001). Sulphonylurea-treated patient …
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
Scott R, Best J, Forder P, Taskinen MR, Simes J, Barter P, Keech A; FIELD Study Investigators. Scott R, et al. Among authors: Forder P. Cardiovasc Diabetol. 2005 Aug 22;4:13. doi: 10.1186/1475-2840-4-13. Cardiovasc Diabetol. 2005. PMID: 16111499 Free PMC article. Clinical Trial.
Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer: A Randomized Clinical Trial.
Janda M, Gebski V, Davies LC, Forder P, Brand A, Hogg R, Jobling TW, Land R, Manolitsas T, Nascimento M, Neesham D, Nicklin JL, Oehler MK, Otton G, Perrin L, Salfinger S, Hammond I, Leung Y, Sykes P, Ngan H, Garrett A, Laney M, Ng TY, Tam K, Chan K, Wrede CD, Pather S, Simcock B, Farrell R, Robertson G, Walker G, Armfield NR, Graves N, McCartney AJ, Obermair A. Janda M, et al. Among authors: Forder P. JAMA. 2017 Mar 28;317(12):1224-1233. doi: 10.1001/jama.2017.2068. JAMA. 2017. PMID: 28350928 Clinical Trial.
The disease-free survival rate difference was 0.3% (favoring TLH; 95% CI, -5.5% to 6.1%; P = .007), meeting criteria for equivalence. There was no statistically significant between-group difference in recurrence of endometrial cancer (28/353 in TAH group [7.9%] vs 33/407 in TLH group [8.1%]; risk difference, 0.2% [95% CI, -3.7% to 4.0%]; P = .93) or in overall survival (24/353 in TAH group [6.8%] vs 30/407 in TLH group [7.4%]; risk difference, 0.6% [95% CI, -3.0% to 4.2%]; P = .76). ...
The disease-free survival rate difference was 0.3% (favoring TLH; 95% CI, -5.5% to 6.1%; P = .007), meeting criteria for equivalence. …
Stroke, Physical Function, and Death Over a 15-Year Period in Older Australian Women.
Hubbard IJ, Vo K, Forder PM, Byles JE. Hubbard IJ, et al. Among authors: Forder PM. Stroke. 2016 Apr;47(4):1060-7. doi: 10.1161/STROKEAHA.115.011456. Epub 2016 Mar 1. Stroke. 2016. PMID: 26931157
The 10-year mortality rate was 37% for women with stroke and adequate PF and 51% for women with stroke and poor PF at the time of the stroke (hazard rate ratio, 1.52; 95% CI, 1.18-1.95; P=0.0015 adjusting for demographic and health covariates). ...
The 10-year mortality rate was 37% for women with stroke and adequate PF and 51% for women with stroke and poor PF at the time of the stroke …
Impact of asthma on mortality in older women: An Australian cohort study of 10,413 women.
Eftekhari P, Forder PM, Majeed T, Byles JE. Eftekhari P, et al. Among authors: Forder PM. Respir Med. 2016 Oct;119:102-108. doi: 10.1016/j.rmed.2016.08.026. Epub 2016 Aug 30. Respir Med. 2016. PMID: 27692129
Women with asthma had a higher likelihood of heart disease, hypertension, thrombosis, bronchitis/emphysema, osteoporosis and major illnesses (p < 0.0001). Asthma was associated with increased risk of death (HR = 1.31, 95%CI 1.18-1.45, p < 0.0001). After adjusting for age, demographic factors, comorbidities, risk factors, residential area and social support, women with asthma retained a 17% increased risk of death compared to women without asthma (HR = 1.17, 95%CI 1.03-1.32, p = 0.016). ...
Women with asthma had a higher likelihood of heart disease, hypertension, thrombosis, bronchitis/emphysema, osteoporosis and major illnesses …
Predictors of 15-year survival among Australian women with diabetes from age 76-81.
Wubishet BL, Harris ML, Forder PM, Acharya SH, Byles JE. Wubishet BL, et al. Among authors: Forder PM. Diabetes Res Clin Pract. 2019 Apr;150:48-56. doi: 10.1016/j.diabres.2019.02.016. Epub 2019 Feb 23. Diabetes Res Clin Pract. 2019. PMID: 30807777
Lower preoperative quality of life increases postoperative risk of adverse events in women with endometrial cancer: results from the LACE trial.
Baker J, Janda M, Gebski V, Forder P, Hogg R, Manolitsas T, Obermair A. Baker J, et al. Among authors: Forder P. Gynecol Oncol. 2015 Apr;137(1):102-5. doi: 10.1016/j.ygyno.2015.02.008. Epub 2015 Feb 14. Gynecol Oncol. 2015. PMID: 25684217 Clinical Trial.
RESULTS: After adjusting for other factors, odds of occurrence of AE of CTC grade≥3 were significantly increased with each unit decrease in baseline FACT-G score (OR=1.02, 95% CI 1.00-1.03, p=0.030), which was driven by physical well-being (PWB) (OR=1.09, 95% CI 1.04-1.13, p=0.0002) and functional well-being subscales (FWB) (OR=1.04, 95% CI 1.00-1.07, p=0.035). Similarly, odds of SAE occurrence were significantly increased with each unit decrease in baseline FACT-G score (OR=1.02, 95% CI 1.01-1.04, p=0.011), baseline PWB (OR=1.11, 95% CI 1.06-1.16, p<0.0001) or baseline FWB subscales (OR=1.05, 95% CI 1.01-1.10, p=0.0077). ...
RESULTS: After adjusting for other factors, odds of occurrence of AE of CTC grade≥3 were significantly increased with each unit decrease in …
52 results
Jump to page
Feedback